Patents by Inventor Kristian Kjaergaard

Kristian Kjaergaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20220177557
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: August 11, 2021
    Publication date: June 9, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY
    Publication number: 20220010012
    Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: July 20, 2021
    Publication date: January 13, 2022
    Inventors: Anette HENRIKSEN, Kristian KJAERGAARD, Vibeke Westphal STENNICKE, Charlotte WIBERG
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 11111290
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 7, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • THERAPEUTIC ANTIBODIES
    Publication number: 20210238300
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Application
    Filed: December 18, 2020
    Publication date: August 5, 2021
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
    Patent number: 11072654
    Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: July 27, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Anette Henriksen, Kristian Kjaergaard, Vibeke Westphal Stennicke, Charlotte Wiberg
  • Anti-C5a receptor antibodies
    Patent number: 10882916
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 5, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10647762
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 12, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20200109192
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 9, 2020
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTI-C5a RECEPTOR ANTIBODIES
    Publication number: 20200017599
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 16, 2020
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10487142
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: November 26, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antibodies specific for hyperphosphorylated tau and methods of use
    Patent number: 10472415
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 12, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjærgaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20190284265
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: April 1, 2019
    Publication date: September 19, 2019
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20190284266
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: April 1, 2019
    Publication date: September 19, 2019
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY
    Publication number: 20190185560
    Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: November 28, 2018
    Publication date: June 20, 2019
    Applicant: Novo Nordisk A/S
    Inventors: Anette HENRIKSEN, Kristian KJAERGAARD, Vibeke Westphal STENNICKE, Charlotte WIBERG
  • Anti-C5a receptor antibodies
    Patent number: 10323097
    Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: June 18, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
    Patent number: 10179814
    Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: January 15, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Anette Henriksen, Kristian Kjærgaard, Vibeke Westphal Stennicke, Charlotte Wiberg
  • Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof
    Publication number: 20180016330
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 18, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjærgaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antagonistic DR3 Ligands
    Publication number: 20170305994
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 26, 2017
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY
    Publication number: 20170298130
    Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: July 17, 2015
    Publication date: October 19, 2017
    Applicant: NOVO NORDISK A/S
    Inventors: Anette Henriksen, Kristian Kjærgaard, Vibeke Westphal Stennicke, Charlotte Wiberg
  • Antagonistic DR3 ligands
    Patent number: 9737612
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: August 22, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard